0%
Print report
Variant interpretation report

CTNNB1 c.2009A>G, p.Tyr670Cys

NM_001904.4:c.2009A>G NP_001895.1:p.(Tyr670Cys) Missense · exon 13 View identifiers
Classification
Uncertain significance

Variant description:

The CTNNB1 NM_001904.4:c.2009A>G (NP_001895.1:p.(Tyr670Cys)) missense variant has previously been reported in somatic cancers (COSMIC; COSV115289897, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About CTNNB1

CTNNB1 encodes beta-catenin, a protein with dual roles in cell adhesion and gene regulation. It is part of the adherens junctions that maintain epithelial cell layers by controlling cell growth and cell-cell adhesion, and it also anchors the actin cytoskeleton and helps transmit the signal that stops cells from dividing once a tissue layer is complete. In the WNT signaling pathway, beta-catenin acts as a transcriptional activator that switches on growth-related genes such as Cyclin D1 and MYC. The gene is associated with colorectal cancer, pilomatrixoma, medulloblastoma, and ovarian cancer, and it acts as an oncogene: excessive beta-catenin activity is common in many solid tumors, including uterine, ovarian, liver, and colorectal cancers.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met, Moderate: the variant was absent from gnomAD v2.1 and v4.1, below the <=0.01% PM2 threshold.

Benign criteria applied · 1
BP1Supporting
BP1 · supporting

Met, supporting: CTNNB1 disease data include 118 truncating versus 4 missense variants, a PTC:missense ratio of 29.5.

Recorded classification: Uncertain significance

VUS: PM2 moderate plus BP1 supporting does not meet any generic ACMG/AMP 2015 pathogenic or benign combination threshold.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

No screenshot for this evidence
REVEL score
0.440 recorded score

Recorded REVEL score: 0.440. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. CTNNB1 (β-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV115289897, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 9 not met · 12 not assessed · 5 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

The adjudicated evidence is limited to PS1, PM1, PM5, PP2, and BP1; BP1 is met at supporting strength because CTNNB1 disease cohorts are predominantly truncating, while PS1 and PM5 lack verified pathogenic amino-acid or same-residue missense comparators.

PM1 is not met because Tyr670 functional importance does not establish a qualifying ACMG/AMP critical domain or hotspot, and PP2 is not met because missense variants are uncommon relative to truncating variants in the cited CTNNB1 disease cohorts.

Neither PS3 nor BS3 is assessed because the available functional studies did not directly test p.Tyr670Cys; residue-level or other-variant findings cannot substitute for variant-specific assay evidence.

No VCEP covers CTNNB1 in this case; generic ACMG/AMP 2015 definitions govern.

The exact variant is NM_001904.4:c.2009A>G (NP_001895.1:p.(Tyr670Cys)).

No exact-variant clinical case-control, case-specific phenotype, expert-panel ClinVar classification, or alternate molecular-basis report was available.

This is a missense variant, so PP3 and BP4 use the mutually exclusive REVEL path only; REVEL 0.44 lies between the supplied PP3 and BP4 cutoffs, so neither criterion is met.

Met · 2

PM2 ModerateACMG_2015Met, Moderate: the variant was absent from gnomAD v2.1 and v4.1, below the <=0.01% PM2 threshold. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength. NM_001904.4:c.2009A>G (CTNNB1 p.Tyr670Cys) was absent from gnomAD v2.1, gnomAD v4.1, and the available gnomAD non-cancer subsets. The generic ACMG/AMP 2015 cutoff supplied for PM2 is <=0.0001 (0.01%), and absence is below this extremely-low-frequency threshold.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 reported the variant as absent.
  • gnomAD v4.1 reported the variant as absent.
  • The available gnomAD v2.1 non-cancer and v3.1 non-cancer results also reported the variant as absent.
  • The generic PM2 cutoff supplied for this case is <=0.0001 (0.01%); an absent variant is below this threshold.
  • The variant is a single-nucleotide substitution, so the ACMG/AMP caveat about poorly called indels does not apply.
Sources
gnomad_v2 ↗gnomad_v4 ↗generic_acmg_combination_rules
BP1 SupportingACMG_2015Met, supporting: CTNNB1 disease data include 118 truncating versus 4 missense variants, a PTC:missense ratio of 29.5. Details ▾Hide ▴
Reasoning

The variant is a missense substitution. In a CTNNB1 neurodevelopmental cohort, only 4 missense variants were reported compared with 118 protein-truncating variants, yielding a PTC:missense ratio of 29.5. A separate CTNNB1 cohort states that most reported pathogenic variants are loss-of-function frameshift, nonsense, or splicing variants, with only a few missense cases. This supports BP1 at the Richards 2015 supporting strength.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • PMID:40684264, Results: only four missense variants were reported, giving a PTC:missense ratio of 29.5 (118:4).
  • PMID:36153650, Discussion: the majority of reported pathogenic CTNNB1 variants are frameshift, nonsense, or splicing variants, except for a few missense cases.
Sources

Not met · 9 · evaluated, threshold not reached

PM1 ACMG_2015Not met: Y670 has functional importance, but no qualifying critical domain or statistically significant hotspot was established, and COSMIC reports only one occurrence. Details ▾Hide ▴
Reasoning

CTNNB1 has no VCEP domain table in vcep_materials.json. The reviewed functional papers show that Tyr670 participates in beta-catenin signaling, but they test Y670F/Y670E or Y654F/Y670F rather than establishing a critical and well-established functional domain for PM1. Cancer Hotspots returned no statistically significant hotspot at Y670, and COSMIC reports only one somatic occurrence of this exact variant, which is not evidence of a hotspot. No benign-variation exclusion for a qualifying domain or hotspot was established.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Zeng et al. 2006 (PMID:16952352): engineered Y670F/Y670E substitutions and concluded that intact Tyr670 is crucial in HGF-mediated beta-catenin translocation, activation, and mitogenesis; this is residue-level functional evidence, not a defined critical domain or validated PM1 hotspot.
  • The Ron/beta-catenin study (PMID:21423209) tested a Y654F/Y670F double mutant and showed signaling effects, but did not establish a PM1-qualifying domain or pathogenicity of Y670C.
  • Cancer Hotspots query CTNNB1 Y670: no statistically significant hotspot row found.
  • COSMIC record COSV115289897: CTNNB1 c.2009A>G reported once in somatic cancer (n = 1), insufficient to establish a hotspot.
Sources
PP2 ACMG_2015Not met: CTNNB1 disease cohorts show 118 truncating versus 4 missense variants, with a PTC:missense ratio of 29.5 rather than a common missense mechanism. Details ▾Hide ▴
Reasoning

PP2 requires both a low rate of benign missense variation and missense variants as a common disease mechanism. The CTNNB1 neurodevelopmental cohort reported 118 truncating variants and only 4 missense variants, a PTC:missense ratio of 29.5, while another CTNNB1 cohort states that most pathogenic variants are loss-of-function. Thus missense is not a common mechanism in the cited disease context, so PP2 is not met.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • PMID:40684264, Results: only four missense variants were reported, giving a PTC:missense ratio of 29.5 (118:4).
  • PMID:36153650, Discussion: the majority of reported pathogenic CTNNB1 variants are frameshift, nonsense, or splicing variants, except for a few missense cases.
Sources
PP3 ACMGNot met: missense REVEL score 0.44 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001904.4:c.2009A>G (p.Tyr670Cys), so the governing generic rule selects the REVEL path only; SpliceAI is not used for a missense PP3/BP4 decision. The REVEL score is 0.44, below the generic PP3 supporting threshold of >= 0.644, so PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys), exon 13.
  • Local REVEL lookup for NC_000003.12:g.41236642A>G returned REVEL 0.44.
  • Under the supplied ClinGen SVI calibration, Pejaver et al. 2022 (PMID:36413997), REVEL >= 0.644 reaches PP3 supporting; 0.44 does not.
  • SpliceAI returned no score, but the missense-specific rule requires REVEL only; the available Pangolin values and BayesDel score are not used for PP3.
Sources
revel
PP5 ACMG_2015Not met: ClinVar has no exact-variant record, expert-panel submission, or qualifying pathogenic assertion for NM_001904.4:c.2009A>G. Details ▾Hide ▴
Reasoning

No exact-variant ClinVar expert-panel classification or other qualifying reputable-source pathogenic assertion was identified. ClinVar reports no result for NM_001904.4:c.2009A>G, with zero submissions and zero expert-panel submissions; therefore PP5 is not met under the stated restriction that ordinary laboratory, aggregate, and non-expert assertions cannot trigger this criterion.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar lookup reports the exact variant as absent, with no variation ID, no submissions, and zero expert-panel submissions.
  • No literature or other reputable-source exact-variant pathogenic classification was identified in the reviewed evidence.
BA1 ACMG_2015Not met: the variant was absent from gnomAD v2.1 and v4.1, far below the 5% BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. NM_001904.4:c.2009A>G (CTNNB1 p.Tyr670Cys) was absent from gnomAD v2.1, gnomAD v4.1, and the available non-cancer subsets, so no allele frequency reaches the 5% stand-alone benign threshold. No VCEP-specific population source or threshold applies.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 reported the variant as absent.
  • gnomAD v4.1 reported the variant as absent.
  • The available gnomAD v2.1 non-cancer and v3.1 non-cancer results also reported the variant as absent; no governing VCEP requires a different population source.
  • The generic BA1 calibration supplied for this case is >=0.05 (5%).
Sources
gnomad_v2 ↗gnomad_v4 ↗generic_acmg_combination_rules
BS1 ACMG_2015Not met: gnomAD reported no observed alleles, so filtering allele frequency is 0 and below the generic 1% BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met. The variant was absent from gnomAD v2.1, gnomAD v4.1, and the available non-cancer subsets, so its filtering allele frequency is not greater than expected for the disorder and does not reach the generic 1% default threshold. Because there is no elevated ancestry-specific frequency, a maximum-credible-frequency calculation is not needed to avoid applying BS1.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v2.1 reported the variant as absent.
  • gnomAD v4.1 reported the variant as absent.
  • The available gnomAD v2.1 non-cancer and v3.1 non-cancer results also reported the variant as absent.
  • No population-specific filtering allele frequency or observed-allele count was available; therefore there is no grpmax FAF or popmax point estimate supporting BS1.
  • The generic BS1 default supplied for this case is >=0.01 (1%); the absence result is below that threshold.
Sources
gnomad_v2 ↗gnomad_v4 ↗generic_acmg_combination_rules
BP4 ACMGNot met: missense REVEL score 0.44 is above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001904.4:c.2009A>G (p.Tyr670Cys), so the governing generic rule selects the REVEL path only; SpliceAI is not used for a missense PP3/BP4 decision. The REVEL score is 0.44, above the generic BP4 supporting threshold of <= 0.29, so BP4 is not met. The missing SpliceAI result cannot be treated as a no-impact prediction, and BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys), exon 13.
  • Local REVEL lookup for NC_000003.12:g.41236642A>G returned REVEL 0.44.
  • Under the supplied ClinGen SVI calibration, Pejaver et al. 2022 (PMID:36413997), REVEL <= 0.29 reaches BP4 supporting; 0.44 does not.
  • SpliceAI returned no score, but a missense variant's BP4 decision cannot substitute SpliceAI for REVEL or treat missing SpliceAI as evidence of no splice impact.
Sources
revel
BP5 ACMG_2015Not met: no clinical case documents this variant alongside an alternate molecular basis for the disease; the single COSMIC somatic entry is insufficient. Details ▾Hide ▴
Reasoning

No qualifying report was found showing this variant in a case with an alternate molecular basis for the disease. The only variant-specific database observation is a single somatic COSMIC entry, which does not establish a germline disease case or an alternate molecular basis for the phenotype under evaluation; no clinical case with an independent molecular diagnosis is documented.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • COSMIC reports the variant once as a somatic cancer observation (COSV115289897, n=1), without a clinical germline case or alternate molecular diagnosis for the disease under evaluation.
  • No reviewed publication reports the exact variant in a patient with an independently established alternate molecular basis.
Sources
BP6 ACMG_2015Not met: ClinVar has no exact-variant record, expert-panel submission, or qualifying benign assertion for NM_001904.4:c.2009A>G. Details ▾Hide ▴
Reasoning

No exact-variant ClinVar expert-panel benign or likely benign classification, or other qualifying reputable-source benign assertion, was identified. ClinVar reports no result for NM_001904.4:c.2009A>G, with zero submissions and zero expert-panel submissions; therefore BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar lookup reports the exact variant as absent, with no variation ID, no submissions, and zero expert-panel submissions.
  • No reviewed literature or other reputable source provides an exact-variant benign or likely benign classification.

Not assessed · 12 · no assessment recorded

PS1 ACMG_2015Not assessed: no verified pathogenic variant producing the same CTNNB1 Tyr670Cys amino-acid change was identified. Details ▾Hide ▴
Reasoning

The variant is CTNNB1 p.Tyr670Cys. ClinVar contains no record for the variant, and the reviewed literature extracts do not report this exact amino-acid change or identify an established pathogenic alternative nucleotide change producing Tyr670Cys. The available evidence is insufficient to establish that the same amino-acid change has previously been determined pathogenic; a comprehensive pathogenic-variant search at the same protein change remains a gap.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • ClinVar search: NM_001904.4:c.2009A>G / CTNNB1 p.(Tyr670Cys) absent; no variation ID or submissions were returned.
  • Kayumi et al. 2022 (PMID:36153650): the paper did not explicitly mention c.2009A>G or p.(Tyr670Cys).
  • The 2025 CTNNB1 cohort extract (PMID:40684264) did not report p.(Tyr670Cys); its same-residue observation was p.Y670Ter/p.Y670fs*, not the same amino-acid change.
  • (cited as evidence_refs, but not a source_registry key: clinvar)
Still missing
  • A comprehensive database or literature record establishing a pathogenic CTNNB1 p.Tyr670Cys variant with a different nucleotide change was not available.
Sources
PS2 ACMG_2015Not assessed: no proband phenotype, family-history status, or confirmed maternity and paternity testing is documented for this variant. Details ▾Hide ▴
Reasoning

PS2 cannot be assessed because the available case evidence does not document a proband with the disease, absence of family history, or confirmed maternity and paternity. No parent-specific testing or de novo observation is provided for NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys).

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence contains no proband-level phenotype or family-history assessment for NM_001904.4:c.2009A>G.
  • The case evidence contains no parental genotypes and no confirmation of both maternity and paternity.
Still missing
  • Document the proband's disease phenotype and family-history status.
  • Document variant testing in both biological parents with confirmed maternity and paternity.
PS3 ACMG_2015Not assessed: functional studies tested Y670F/Y670E or other CTNNB1 variants, not the c.2009A>G (p.Tyr670Cys) substitution. Details ▾Hide ▴
Reasoning

No well-established functional study directly tested CTNNB1 NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys). PMID:16952352 tested engineered Y670F, Y670E, and Y654F/Y670F substitutions; PMID:21423209 tested a Y654F/Y670F double mutant; and PMID:40684264 tested other CTNNB1 variants, including p.Y670Ter/p.Y670fs*. These studies establish biological relevance of the residue or gene but do not provide variant-specific evidence that p.Tyr670Cys has a damaging effect, so PS3 cannot be assessed at an ACMG/AMP 2015 strength.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. ... Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well-established.
Evidence considered
  • PMID:16952352: Site-directed CTNNB1 mutagenesis tested Y670F, Y670E, and Y654F/Y670F in transfected rat hepatoma JM1 cells with nuclear-localization, DNA-synthesis, co-immunoprecipitation, phosphotyrosine-immunoblotting, and EMSA assays; p.Tyr670Cys was not tested.
  • PMID:21423209: Ron/HGFL signaling experiments tested a Y654F/Y670F beta-catenin double mutant in breast-cancer models and assessed localization, transcriptional activity, target-gene expression, proliferation, and tumor growth; p.Tyr670Cys was not tested.
  • PMID:40684264: CTNNB1 variant studies used TOPFlash/FOPFlash reporter assays and immunoblotting; the cohort included other variants, including p.Y670Ter/p.Y670fs*, but not p.Tyr670Cys.
Still missing
  • A validated, reproducible functional assay directly comparing p.Tyr670Cys with wild-type CTNNB1 and appropriate controls is needed.
Sources
PS4 ACMG_2015Not assessed: no exact-variant case-control counts or prevalence comparison were available to calculate the required OR/RR and 95% confidence interval. Details ▾Hide ▴
Reasoning

No qualifying case-control comparison for NM_001904.4:c.2009A>G (NP_001895.1:p.(Tyr670Cys)) was identified. The literature packet contains no classified papers, and the reviewed CTNNB1 cohort papers do not mention this exact variant or provide affected-versus-control counts for it; therefore an OR/RR and 95% CI cannot be calculated. The variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada, but absence alone does not establish the ACMG/AMP PS4 case-control requirement or provide the required case prevalence comparison.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • literature_pass.json reports total_pmids=0 and no PS4-classified papers.
  • Yan et al. (PMID:36153650) reviewed 24 CTNNB1-related patients but the paper-extract search found no c.2009A>G, p.(Y670C), or p.(Tyr670Cys) and no exact-variant case/control counts.
  • The reviewed extract for PMID:40684264 describes 127 CTNNB1 neurodevelopmental-syndrome participants and 125 variants, but does not report c.2009A>G or p.(Tyr670Cys); it therefore supplies no exact-variant case prevalence or control comparison.
  • gnomAD v2.1, gnomAD v4.1, and gnomAD-Canada each report the variant as absent; no control numerator, denominator, matched-ancestry frequency, or confidence interval is supplied.
Still missing
  • A case series or case-control study reporting this exact variant in affected individuals and suitable controls is needed.
  • If counts become available, calculate OR/RR and its 95% CI and verify OR/RR >5.0 with a confidence interval excluding 1.0.
Sources
PM5 ACMG_2015Not assessed: experimental Y670 substitutions were reported, but no different pathogenic missense change at Tyr670 was verified. Details ▾Hide ▴
Reasoning

The variant affects Tyr670. The reviewed papers describe experimental substitutions at Tyr670, but do not establish a different missense change at Tyr670 as pathogenic in affected individuals. No verified same-residue pathogenic missense comparator was available, so PM5 cannot be assessed at the required 2015 moderate strength.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • PMID:16952352: Y670F and Y670E were engineered for functional experiments; these are not reported clinical pathogenic missense variants.
  • PMID:21423209: a Y654F/Y670F double mutant was studied experimentally; it is not a clinically established pathogenic Y670 missense comparator.
  • PMID:40684264: p.Y670Ter/p.Y670fs* were reported or tested, but these are truncating variants rather than a different missense change at Tyr670.
  • The PM5 candidate record contained zero verified same-residue comparator candidates and explicitly did not establish classic PM5 semantics.
Still missing
  • A clinically established pathogenic CTNNB1 missense comparator at residue Tyr670 is needed for PM5.
Sources
PM6 ACMG_2015Not assessed: no assumed de novo occurrence or parental genotype data are documented for this variant. Details ▾Hide ▴
Reasoning

PM6 cannot be assessed because the available case evidence does not document an assumed de novo occurrence in the proband. No parental genotypes or evidence establishing de novo status without confirmed maternity and paternity are provided for NM_001904.4:c.2009A>G.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case evidence contains no proband de novo claim and no parental genotype results for NM_001904.4:c.2009A>G.
  • No information is provided to distinguish confirmed de novo status from an assumed de novo observation.
Still missing
  • Document the proband's variant result and clinical context.
  • Document parental testing or other evidence supporting an assumed de novo origin.
PP1 ACMG_2015Not assessed: zero affected relatives or informative co-segregation meioses are documented for this variant. Details ▾Hide ▴
Reasoning

PP1 cannot be assessed because the available case evidence documents no affected relatives, informative meioses, or co-segregation results for NM_001904.4:c.2009A>G. The strength cannot be determined without the number and disease status of informative family members.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • The case evidence contains no affected-family-member genotypes, phenotype descriptions, or segregation table for NM_001904.4:c.2009A>G.
  • No informative meiosis count is available, so PP1 strength cannot be selected.
Still missing
  • Document affected relatives, their phenotypes, and variant genotypes.
  • Document the number of informative meioses and segregation results.
PP4 ACMG_2015Not assessed: no case-specific phenotype or family history was available to show a highly specific CTNNB1 disease presentation. Details ▾Hide ▴
Reasoning

The available case evidence does not provide a patient phenotype or family history for this variant that can be evaluated for high specificity to a single-gene disease. The CTNNB1 publications reviewed describe disease cohorts generally, but neither reports this exact variant in the present case or supplies a case-specific phenotype/family-history record. Therefore the PP4 specificity requirement cannot be assessed.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • The case summary identifies CTNNB1 and the p.(Tyr670Cys) variant but does not provide a patient-specific phenotype or family history.
  • PMID:36153650 reports general manifestations in a CTNNB1-related cohort, but the exact variant was not mentioned and the cohort findings cannot substitute for this patient's phenotype.
  • PMID:40684264 reports a CTNNB1 neurodevelopmental-syndrome cohort, but the exact variant was not mentioned and no case-specific phenotype is available here.
Still missing
  • A documented phenotype and family history for the individual carrying NM_001904.4:c.2009A>G are needed.
  • The phenotype must be evaluated for high specificity to a disease with a single genetic etiology.
Sources
BS2 ACMG_2015Not assessed: no healthy adult carrying the variant with the required zygosity and early-onset full-penetrance context was documented. Details ▾Hide ▴
Reasoning

BS2 is not assessed. The available evidence contains population-level absence results but no observation of this variant in a healthy adult individual, and no individual-level zygosity, age, phenotype, penetrance, or inheritance information. Population absence cannot establish the BS2 healthy-adult observation requirement.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • The available gnomAD records report absence of the variant rather than a healthy adult carrier observation.
  • No case-specific individual-level evidence documents a healthy heterozygous adult with CTNNB1 p.Tyr670Cys.
Still missing
  • A documented healthy adult observation with the relevant zygosity and adequate age/phenotype information is unavailable.
BS3 ACMG_2015Not assessed: no validated assay directly showed that p.Tyr670Cys has no damaging effect on CTNNB1 protein function or splicing. Details ▾Hide ▴
Reasoning

No well-established functional study directly tested CTNNB1 NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys) and showed no damaging effect on protein function or splicing. PMID:16952352, PMID:21423209, and PMID:40684264 evaluated different engineered substitutions or different CTNNB1 variants, with results that cannot be transferred as variant-specific benign evidence for p.Tyr670Cys. Therefore BS3 cannot be assessed at an ACMG/AMP 2015 strength.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:16952352: Y670F, Y670E, and Y654F/Y670F substitutions were studied, but these are not p.Tyr670Cys and do not establish absence of damaging effect for the case variant.
  • PMID:21423209: A Y654F/Y670F double mutant altered Ron-dependent beta-catenin signaling, but the double-mutant result does not evaluate p.Tyr670Cys or establish benign function for it.
  • PMID:40684264: Functional reporter and protein-level analyses concerned other CTNNB1 variants, including p.Y670Ter/p.Y670fs*, not p.Tyr670Cys.
Still missing
  • A validated, reproducible functional assay directly testing p.Tyr670Cys with appropriate wild-type and benign controls is needed to evaluate BS3.
Sources
BS4 ACMG_2015Not assessed: no affected relatives with documented absence of the variant are reported. Details ▾Hide ▴
Reasoning

BS4 cannot be assessed because the available case evidence identifies no affected family members who were tested and found not to carry NM_001904.4:c.2009A>G. No non-segregation observations or phenocopy assessment are documented.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The case evidence contains no affected-relative testing results showing absence of NM_001904.4:c.2009A>G.
  • No family-level non-segregation data or assessment of phenocopies is provided.
Still missing
  • Document affected relatives who were evaluated for the variant.
  • Document their genotypes, phenotypes, and any phenocopy or alternative-cause assessment.
BP2 ACMG_2015Not assessed: no affected-proband observation or phase testing establishes this variant in trans or cis with a pathogenic variant. Details ▾Hide ▴
Reasoning

BP2 requires an observation of this variant in trans with a pathogenic variant for a fully penetrant dominant disorder, or in cis with a pathogenic variant in any inheritance pattern. The available evidence contains no affected-proband observation with a second pathogenic allele and no parental, offspring, or other phase testing establishing cis or trans. The criterion therefore cannot be assessed.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Still missing
  • Affected-proband case data with the accompanying pathogenic variant are needed.
  • Parental, offspring, or other validated phase testing is needed to establish cis or trans configuration.
Not applicable · 5· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_001904.4:c.2009A>G in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Tyr670Cys). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM3 N/ANot applicable: CTNNB1 neurodevelopmental disorder is described as autosomal dominant with heterozygous variants, whereas PM3 is restricted to recessive disorders. Details ▾Hide ▴
Reasoning

PM3 is restricted to recessive disorders and requires the variant to be detected in trans with a pathogenic variant, with parental or offspring testing to establish phase. The available CTNNB1 disease literature describes the relevant neurodevelopmental disorder as autosomal dominant and caused by heterozygous germline variants; therefore PM3 is not applicable to this disorder. No PM3 strength is assigned.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • Yan et al. 2022, PMID:36153650, abstract: the CTNNB1-related neurodevelopmental disorder is described as a rare autosomal dominant syndrome caused by heterozygous germline loss-of-function variants; this establishes that the PM3 recessive-disorder pathway is not applicable.
Sources
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001904.4:c.2009A>G in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Tyr670Cys). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001904.4:c.2009A>G in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Tyr670Cys). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001904.4:c.2009A>G in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Tyr670Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
CTNNB1
Transcript
NM_001904.4
Coding (HGVS c.)
NM_001904.4:c.2009A>G
Protein (HGVS p.)
NP_001895.1:p.(Tyr670Cys)
GRCh38
chr3:41236642 A>G
GRCh37
chr3:41278133 A>G
Location and type
Exon 13 · missense
COSMIC
COSV115289897

Gene diagram

Every interpreted variant in CTNNB1, mapped onto the exon structure of NM_001904.4. Select a row to find it on the plot.

CTNNB1NM_001904.4
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

Pangolin splice lossmagnitude shown
-0.003
Pangolin splice gain
0.001

Other predictors

REVEL
0.440
BayesDel
0.000

How the predictions were used

PP3 ACMGNot met: missense REVEL score 0.44 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001904.4:c.2009A>G (p.Tyr670Cys), so the governing generic rule selects the REVEL path only; SpliceAI is not used for a missense PP3/BP4 decision. The REVEL score is 0.44, below the generic PP3 supporting threshold of >= 0.644, so PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys), exon 13.
  • Local REVEL lookup for NC_000003.12:g.41236642A>G returned REVEL 0.44.
  • Under the supplied ClinGen SVI calibration, Pejaver et al. 2022 (PMID:36413997), REVEL >= 0.644 reaches PP3 supporting; 0.44 does not.
  • SpliceAI returned no score, but the missense-specific rule requires REVEL only; the available Pangolin values and BayesDel score are not used for PP3.
Sources
revel
BP4 ACMGNot met: missense REVEL score 0.44 is above the BP4 supporting threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001904.4:c.2009A>G (p.Tyr670Cys), so the governing generic rule selects the REVEL path only; SpliceAI is not used for a missense PP3/BP4 decision. The REVEL score is 0.44, above the generic BP4 supporting threshold of <= 0.29, so BP4 is not met. The missing SpliceAI result cannot be treated as a no-impact prediction, and BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001904.4:c.2009A>G (NP_001895.1:p.Tyr670Cys), exon 13.
  • Local REVEL lookup for NC_000003.12:g.41236642A>G returned REVEL 0.44.
  • Under the supplied ClinGen SVI calibration, Pejaver et al. 2022 (PMID:36413997), REVEL <= 0.29 reaches BP4 supporting; 0.44 does not.
  • SpliceAI returned no score, but a missense variant's BP4 decision cannot substitute SpliceAI for REVEL or treat missing SpliceAI as evidence of no splice impact.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001904.4:c.2009A>G in CTNNB1 is a missense substitution predicted to produce NP_001895.1:p.(Tyr670Cys). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for CTNNB1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI returned NO scores for this variant, so no SpliceAI-based splice prediction is available. This is missing data, NOT evidence of absent splice impact: it must not be used to support BP4 or to argue against PP3/PVS1. Pangolin scores may be present but are not calibrated for PP3/BP4 here. REVEL score = 0.44. BayesDel score = 4.23961e-05.

0 paper records listed. 2 cited in the classification.

Cited in the classification

  • Genetic and clinical characteristics of 24 mainland Chinese patients with CTNNB1
    This paper describes CTNNB1-related neurodevelopmental disorder and states that most reported pathogenic CTNNB1 variants are loss-of-function frameshift, nonsense, or splicing variants, with only a few missense cases. It does not explicitly mention c.2009A>G or p.Tyr670Cys.
    → BP1 · supporting Does not name this variant
    PMID 36153650 ↗
    Source detail
    The majority of reported pathogenic variants in CTNNB1 are loss-of-function variants such as frameshift, nonsense, or splicing variants, except for a few cases with missense variants.

    Location Discussion, genotype paragraph

    Context Clinical and molecular characterization of 24 Chinese patients with CTNNB1-related NEDSDV; sequencing was performed primarily by exome sequencing (23/24 patients), with variants unified to CTNNB1 transcript NM_001904.4.

  • Genotypic, functional, and phenotypic characterization in CTNNB1 neurodevelopmen
    This CTNNB1 neurodevelopmental syndrome cohort included 127 individuals and 125 curated variants; only four were missense, producing a PTC:missense ratio of 29.5 (118:4). It did not report p.Tyr670Cys; p.Y670Ter/p.Y670fs* observations were truncating rather than missense comparators.
    → BP1 · supporting Does not name this variant
    PMID 40684264 ↗
    Source detail
    Only four missense variants were reported, giving a PTC:missense ratio of 29.5 (118:4).

    Location Results, Analysis of CTNNB1 variants in neurodevelopmental disorders; Results, CTNNB1 variants can both perturb and stimulate the Wnt/beta-catenin pathway

    Context Cross-sectional cohort of 127 participants with genetically confirmed CTNNB1 variants; CTNNB1 variant curation; TOPFlash/FOPFlash dual-luciferase assays and immunoblotting in SK-N-MC human neuroblastoma cells using mutant CTNNB1 constructs.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI returned NO scores for this variant, so no SpliceAI-based splice prediction is available. This is missing data, NOT evidence of absent splice impact: it must not be used to support BP4 or to argue against PP3/PVS1. Pangolin scores may be present but are not calibrated for PP3/BP4 here. REVEL score = 0.44. BayesDel score = 4.23961e-05.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. CTNNB1 (β-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV115289897, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.